Systematic review of the use of retrievable inferior vena cava filters

Luis F. Angel, Victor Tapson, Richard E. Galgon, Marcos I. Restrepo, John Kaufman

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

Purpose: To review the available literature on retrievable inferior vena cava (IVC) filters to examine the effectiveness and risks of these devices. Materials and Methods: Investigators searched MEDLINE for clinical trials evaluating retrievable filters and reviewed the complications reported to the Manufacturer and User Facility Device Experience (MAUDE) database of the U.S. Food and Drug Administration (FDA). Results: Eligibility criteria were met by 37 studies comprising 6,834 patients. All of the trials had limitations, and no studies were randomized. There were 11 prospective clinical trials; the rest were retrospective studies. Despite the limitations of the evidence, the IVC filters seemed to be effective in preventing pulmonary embolism (PE); the rate of PE after IVC placement was 1.7%. The mean retrieval rate was 34%. Most of the filters became permanent devices. Multiple complications associated with the use of IVC filters were described in the reviewed literature or were reported to the MAUDE database; most of these were associated with long-term use (> 30 days). At the present time, the objective comparison data of different filter designs do not support superiority of any particular design. Conclusions: In high-risk patients for whom anticoagulation is not feasible, retrievable IVC filters seem to be effective in preventing PE. Long-term complications are a serious concern with the use of these filters. The evidence of the effectiveness and the risks was limited by the small number of prospective studies.

Original languageEnglish (US)
JournalJournal of Vascular and Interventional Radiology
Volume22
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Vena Cava Filters
Pulmonary Embolism
Equipment and Supplies
Clinical Trials
Databases
Inferior Vena Cava
United States Food and Drug Administration
MEDLINE
Retrospective Studies
Research Personnel
Prospective Studies

Keywords

  • ACCP
  • American College of Chest Physicians
  • CI
  • confidence interval
  • deep vein thrombosis
  • DVT
  • FDA
  • inferior vena cava
  • IVC
  • Manufacturer and User Facility Device Experience
  • MAUDE
  • PE
  • pulmonary embolism
  • U.S. Food and Drug Administration
  • venous thromboembolism
  • VTE

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Systematic review of the use of retrievable inferior vena cava filters. / Angel, Luis F.; Tapson, Victor; Galgon, Richard E.; Restrepo, Marcos I.; Kaufman, John.

In: Journal of Vascular and Interventional Radiology, Vol. 22, No. 11, 11.2011.

Research output: Contribution to journalArticle

Angel, Luis F. ; Tapson, Victor ; Galgon, Richard E. ; Restrepo, Marcos I. ; Kaufman, John. / Systematic review of the use of retrievable inferior vena cava filters. In: Journal of Vascular and Interventional Radiology. 2011 ; Vol. 22, No. 11.
@article{6905f3e5839d43e8a114dad6373bf428,
title = "Systematic review of the use of retrievable inferior vena cava filters",
abstract = "Purpose: To review the available literature on retrievable inferior vena cava (IVC) filters to examine the effectiveness and risks of these devices. Materials and Methods: Investigators searched MEDLINE for clinical trials evaluating retrievable filters and reviewed the complications reported to the Manufacturer and User Facility Device Experience (MAUDE) database of the U.S. Food and Drug Administration (FDA). Results: Eligibility criteria were met by 37 studies comprising 6,834 patients. All of the trials had limitations, and no studies were randomized. There were 11 prospective clinical trials; the rest were retrospective studies. Despite the limitations of the evidence, the IVC filters seemed to be effective in preventing pulmonary embolism (PE); the rate of PE after IVC placement was 1.7{\%}. The mean retrieval rate was 34{\%}. Most of the filters became permanent devices. Multiple complications associated with the use of IVC filters were described in the reviewed literature or were reported to the MAUDE database; most of these were associated with long-term use (> 30 days). At the present time, the objective comparison data of different filter designs do not support superiority of any particular design. Conclusions: In high-risk patients for whom anticoagulation is not feasible, retrievable IVC filters seem to be effective in preventing PE. Long-term complications are a serious concern with the use of these filters. The evidence of the effectiveness and the risks was limited by the small number of prospective studies.",
keywords = "ACCP, American College of Chest Physicians, CI, confidence interval, deep vein thrombosis, DVT, FDA, inferior vena cava, IVC, Manufacturer and User Facility Device Experience, MAUDE, PE, pulmonary embolism, U.S. Food and Drug Administration, venous thromboembolism, VTE",
author = "Angel, {Luis F.} and Victor Tapson and Galgon, {Richard E.} and Restrepo, {Marcos I.} and John Kaufman",
year = "2011",
month = "11",
doi = "10.1016/j.jvir.2011.08.024",
language = "English (US)",
volume = "22",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Systematic review of the use of retrievable inferior vena cava filters

AU - Angel, Luis F.

AU - Tapson, Victor

AU - Galgon, Richard E.

AU - Restrepo, Marcos I.

AU - Kaufman, John

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To review the available literature on retrievable inferior vena cava (IVC) filters to examine the effectiveness and risks of these devices. Materials and Methods: Investigators searched MEDLINE for clinical trials evaluating retrievable filters and reviewed the complications reported to the Manufacturer and User Facility Device Experience (MAUDE) database of the U.S. Food and Drug Administration (FDA). Results: Eligibility criteria were met by 37 studies comprising 6,834 patients. All of the trials had limitations, and no studies were randomized. There were 11 prospective clinical trials; the rest were retrospective studies. Despite the limitations of the evidence, the IVC filters seemed to be effective in preventing pulmonary embolism (PE); the rate of PE after IVC placement was 1.7%. The mean retrieval rate was 34%. Most of the filters became permanent devices. Multiple complications associated with the use of IVC filters were described in the reviewed literature or were reported to the MAUDE database; most of these were associated with long-term use (> 30 days). At the present time, the objective comparison data of different filter designs do not support superiority of any particular design. Conclusions: In high-risk patients for whom anticoagulation is not feasible, retrievable IVC filters seem to be effective in preventing PE. Long-term complications are a serious concern with the use of these filters. The evidence of the effectiveness and the risks was limited by the small number of prospective studies.

AB - Purpose: To review the available literature on retrievable inferior vena cava (IVC) filters to examine the effectiveness and risks of these devices. Materials and Methods: Investigators searched MEDLINE for clinical trials evaluating retrievable filters and reviewed the complications reported to the Manufacturer and User Facility Device Experience (MAUDE) database of the U.S. Food and Drug Administration (FDA). Results: Eligibility criteria were met by 37 studies comprising 6,834 patients. All of the trials had limitations, and no studies were randomized. There were 11 prospective clinical trials; the rest were retrospective studies. Despite the limitations of the evidence, the IVC filters seemed to be effective in preventing pulmonary embolism (PE); the rate of PE after IVC placement was 1.7%. The mean retrieval rate was 34%. Most of the filters became permanent devices. Multiple complications associated with the use of IVC filters were described in the reviewed literature or were reported to the MAUDE database; most of these were associated with long-term use (> 30 days). At the present time, the objective comparison data of different filter designs do not support superiority of any particular design. Conclusions: In high-risk patients for whom anticoagulation is not feasible, retrievable IVC filters seem to be effective in preventing PE. Long-term complications are a serious concern with the use of these filters. The evidence of the effectiveness and the risks was limited by the small number of prospective studies.

KW - ACCP

KW - American College of Chest Physicians

KW - CI

KW - confidence interval

KW - deep vein thrombosis

KW - DVT

KW - FDA

KW - inferior vena cava

KW - IVC

KW - Manufacturer and User Facility Device Experience

KW - MAUDE

KW - PE

KW - pulmonary embolism

KW - U.S. Food and Drug Administration

KW - venous thromboembolism

KW - VTE

UR - http://www.scopus.com/inward/record.url?scp=80054888214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054888214&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2011.08.024

DO - 10.1016/j.jvir.2011.08.024

M3 - Article

C2 - 22024114

AN - SCOPUS:80054888214

VL - 22

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 11

ER -